靶向GD2的瞬时mRNA CAR T细胞对弥漫性中线胶质瘤和高级别胶质瘤模型提供剂量调整疗效
本研究在细胞系、类器官和体内异种移植模型中评估了经mRNA创建的靶向GD2的瞬时CAR T细胞,采用重复瘤内给药,结果显示其对弥漫性中线胶质瘤和高级别胶质瘤具有活性,细胞毒性在9天内持续减弱,并在脑桥和丘脑DMG异种移植模型中通过下调剂量维持疗效而不引起神经毒性。
要点
- mRNA GD2 CAR T细胞在体外对DMG和高级别胶质瘤细胞系及类器官模型有活性。
- 细胞毒性在9天内持续减弱,提示可避免持续性T细胞活性带来的毒性。
- 在脑桥和丘脑DMG异种移植模型中,重复给药下调剂量可维持疗效且不引起神经毒性。
核心结论
- 经mRNA创建的靶向GD2的瞬时CAR T细胞瘤内递送可提供有效肿瘤杀伤,且具有明确的半衰期,允许调节剂量和潜在副作用。
- 作者预计本研究将扩展CAR T细胞疗法在DMG及其他中枢神经系统肿瘤和非恶性疾病中的应用,这些领域对永久表达CAR T细胞毒性的担忧可能阻碍开发。
研究设计与样本
- 研究在细胞系、类器官和体内异种移植模型中评估经mRNA创建的靶向GD2的瞬时CAR T细胞,采用重复瘤内给药,评估疗效和安全性。
主要发现
- mRNA GD2 CAR T细胞在体外对DMG和高级别胶质瘤的细胞系及类器官模型有活性。
- 细胞毒性在9天内持续减弱。
- 在脑桥和丘脑DMG异种移植模型中,重复剂量的mRNA GD2 CAR T细胞被下调以维持治疗效果而不引起神经毒性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline glioma (DMG) and high-grade glioma are devastating pediatric central nervous system tumors that remain incurable. Recent chimeric antigen receptor (CAR) T cell studies have shown proof of concept and early signs of efficacy against DMG targeting GD2. Prior work and ongoing clinical trials have focused on using viral vectors to create permanent CAR T cells. However, virally transduced GD2-directed CAR T cells have shown significant neurotoxicity in both preclinical models and human trials. METHODS: We evaluated transient CAR T cells targeting GD2 created with mRNA, assessing for efficacy and safety in cell line, organoid, and in vivo xenograft models with repetitive intratumoral dosing. RESULTS: We show that mRNA GD2-directed CAR T cells are active against both cell lines and organoid models of DMG and high-grade glioma in vitro. Cytotoxicity consistently abates over 9 days, highlighting the potential to avoid toxicity from persistent T cell activity. In both pontine and thalamic DMG xenograft models, repeated doses of mRNA GD2-directed CAR T cells were titrated down to maintain therapeutic effects without causing neurologic toxicity. CONCLUSIONS: Our results demonstrate the utility of transient mRNA CAR T cells delivered intratumorally to provide effective tumor killing with a defined half-life, allowing for modulation of the dose and potential side effects. We anticipate this study will expand the use of CAR T cell therapy for DMG and other central nervous system tumors and non-malignant disorders, where concern for toxicity from permanently expressing CAR T cells may hinder development.
引用
- Foster JB, Madsen PJ, Harvey K, et al. Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models. Neuro Oncol. 2025. PMID: 40411488. doi:10.1093/neuonc/noaf115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。